Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up

Impact · against what's priced in

Ionis faces a significant valuation reset following the Phase 3 failure of eplontersen, shifting investor focus to its upcoming PDUFA and hepatitis B decisions. Alnylam stands to benefit from reduced competition in the ATTR-CM market, while other RNA-focused biotechs are experiencing temporary volatility due to sector sympathy.

IONS−0.90

No priced-in read yet